Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reena Sharma

Showing results (131-140 of 146) with videos related to

Pageof 15
Sort By:
Neurology|December 1, 2022
Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 GangliosidosesKyriakos Martakis, Jens Claassen, Jordi Gascon-Bayari, et al.
International Journal of Rheumatic Diseases|July 16, 2015
A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritisRajendrakumar H Jani, Rajiv Gupta, Girish Bhatia, et al.
NPJ Genomic Medicine|December 30, 2025
Author Correction: PHKA1-associated phosphorylase kinase deficiency: a monogenic disorder of exercise intolerance and myalgiaRebecca L Koch, Angie H Fares, Benjamin T Cocanougher, et al.
Drug Design, Development and Therapy|July 18, 2015
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry diseaseLubor Goláň, Ozlem Goker-Alpan, Myrl Holida, et al.
Journal of Neurology|August 13, 2021
Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type CTatiana Bremova-Ertl, Jens Claassen, Tomas Foltan, et al.
International Journal of Rheumatic Diseases|June 2, 2020
Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 yearsArvind Chopra, Vineeta Shobha, Srikantiah Chandrashekara, et al.
Hepatology (Baltimore, Md.)|January 26, 2013
Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage diseaseManisha Balwani, Catherine Breen, Gregory M Enns, et al.
Orphanet Journal of Rare Diseases|October 15, 2021
In-depth phenotyping for clinical stratification of Gaucher diseaseSimona D'Amore, Kathleen Page, Aimée Donald, et al.
Orphanet Journal of Rare Diseases|February 15, 2022
Clinical disease characteristics of patients with Niemann-Pick Disease Type C: findings from the International Niemann-Pick Disease Registry (INPDR)Shaun C Bolton, Vina Soran, Mercedes Pineda Marfa, et al.
Molecular Genetics and Metabolism|July 15, 2025
Long-term efficacy and safety of arimoclomol in Niemann-Pick disease type C: Final results of the phase 2/3 NPC-002 48-month open-label extension trialEugen Mengel, Rosalia M Da Riol, Mireia Del Toro, et al.
Pageof 15

Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
Neurology|December 1, 2022
Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 GangliosidosesKyriakos Martakis, Jens Claassen, Jordi Gascon-Bayari, et al.
International Journal of Rheumatic Diseases|July 16, 2015
A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritisRajendrakumar H Jani, Rajiv Gupta, Girish Bhatia, et al.
NPJ Genomic Medicine|December 30, 2025
Author Correction: PHKA1-associated phosphorylase kinase deficiency: a monogenic disorder of exercise intolerance and myalgiaRebecca L Koch, Angie H Fares, Benjamin T Cocanougher, et al.
Drug Design, Development and Therapy|July 18, 2015
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry diseaseLubor Goláň, Ozlem Goker-Alpan, Myrl Holida, et al.
Journal of Neurology|August 13, 2021
Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type CTatiana Bremova-Ertl, Jens Claassen, Tomas Foltan, et al.
International Journal of Rheumatic Diseases|June 2, 2020
Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 yearsArvind Chopra, Vineeta Shobha, Srikantiah Chandrashekara, et al.
Hepatology (Baltimore, Md.)|January 26, 2013
Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage diseaseManisha Balwani, Catherine Breen, Gregory M Enns, et al.
Orphanet Journal of Rare Diseases|October 15, 2021
In-depth phenotyping for clinical stratification of Gaucher diseaseSimona D'Amore, Kathleen Page, Aimée Donald, et al.
Orphanet Journal of Rare Diseases|February 15, 2022
Clinical disease characteristics of patients with Niemann-Pick Disease Type C: findings from the International Niemann-Pick Disease Registry (INPDR)Shaun C Bolton, Vina Soran, Mercedes Pineda Marfa, et al.
Molecular Genetics and Metabolism|July 15, 2025
Long-term efficacy and safety of arimoclomol in Niemann-Pick disease type C: Final results of the phase 2/3 NPC-002 48-month open-label extension trialEugen Mengel, Rosalia M Da Riol, Mireia Del Toro, et al.
Pageof 15